These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19924144)

  • 21. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
    Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J
    Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
    Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
    Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
    Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.
    Giuntoli S; Rovida E; Barbetti V; Cipolleschi MG; Olivotto M; Dello Sbarba P
    Leukemia; 2006 Jul; 20(7):1291-3. PubMed ID: 16710305
    [No Abstract]   [Full Text] [Related]  

  • 28. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
    Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
    Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
    Skorta I; Oren M; Markwardt C; Gutekunst M; Aulitzky WE; van der Kuip H
    Cancer Res; 2009 Dec; 69(24):9337-45. PubMed ID: 19934315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
    Zong Y; Zhou S; Sorrentino BP
    Leukemia; 2005 Sep; 19(9):1590-6. PubMed ID: 16001089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L; Savranskaya L; Sweatman TW
    Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
    Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
    Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
    Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
    Crowley LC; Elzinga BM; O'Sullivan GC; McKenna SL
    Am J Hematol; 2011 Jan; 86(1):38-47. PubMed ID: 21132731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
    Stein AM; Bottino D; Modur V; Branford S; Kaeda J; Goldman JM; Hughes TP; Radich JP; Hochhaus A
    Clin Cancer Res; 2011 Nov; 17(21):6812-21. PubMed ID: 21903771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
    Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.